Protagonist Therapeutics reports successful Phase 3 results for new psoriasis drug icotrokinra.

Protagonist Therapeutics has reported successful Phase 3 results for icotrokinra, a new oral treatment for moderate to severe plaque psoriasis. In trials, icotrokinra achieved significant skin clearance in 64.7% of patients at week 16, improving to 74.1% by week 24. The drug met primary efficacy endpoints and showed a safety profile consistent with earlier studies. Protagonist earned a $165 million milestone from Johnson & Johnson and is eligible for additional payments and royalties.

November 18, 2024
11 Articles